| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Haniya J Halim, Bradley G Burk, Rachel E Fargason, Badari Biru. Manic episode following psilocybin use in a man with bipolar II disorder: a case report. Frontiers in psychiatry. vol 14. 2023-10-09. PMID:37810598. |
given the incidence of depression in those with bipolar disorder, impulsivity, and a tendency to abuse substances associated with the illness, further research is needed into the risks of psilocybin and other psychedelic use in those with bipolar disorder. |
2023-10-09 |
2023-10-15 |
Not clear |
| Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, David Menkes, William Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, Todd Smith, Partha Roop, Nathan Allen, Binu Abeysinghe, Darren Svirskis, Anna Forsyth, Mahima Bansal, Suresh Muthukumaraswam. An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). Pilot and feasibility studies. vol 9. issue 1. 2023-10-05. PMID:37798662. |
in light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients to self-treat depression with microdoses of psychedelic drugs such as lysergic acid diethylamide (lsd) and psilocybin [3]. |
2023-10-05 |
2023-10-07 |
human |
| Thomas J Kelly, Emma M Bonniwell, Lianwei Mu, Xiaojie Liu, Ying Hu, Vladislav Friedman, Hao Yu, Wantang Su, John D McCorvy, Qing-Song Li. Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-09-26. PMID:37752222. |
psychedelics such as psilocybin show great promise for the treatment of depression and ptsd, but their long duration of action poses practical limitations for patient access. |
2023-09-26 |
2023-10-07 |
human |
| Amir Garakani, Jeanne L Alexander, Calvin R Sumner, Janet H Pine, Lawrence S Gross, Charles L Raison, Scott T Aaronson, David A Baro. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal of psychiatric practice. vol 29. issue 5. 2023-09-07. PMID:37678363. |
while discussing psychedelics in general, the focus of this paper is on psilocybin and its mechanism, how it exerts a psychedelic effect, dosing, and a review of the treatment studies of psilocybin, which were primarily for treatment-resistant depression and cancer-related anxiety. |
2023-09-07 |
2023-10-07 |
Not clear |
| Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet, Dean Calhou. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits. Journal of applied toxicology : JAT. 2023-08-30. PMID:37646119. |
serotonergic psychedelics, such as lysergic acid diethylamide (lsd), psilocybin, dimethyltryptamine (dmt), and 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. |
2023-08-30 |
2023-09-07 |
Not clear |
| Robert F Dougherty, Patrick Clarke, Merve Atli, Joanna Kuc, Danielle Schlosser, Boadie W Dunlop, David J Hellerstein, Scott T Aaronson, Sidney Zisook, Allan H Young, Robin Carhart-Harris, Guy M Goodwin, Gregory A Rysli. Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. Psychopharmacology. 2023-08-22. PMID:37606733. |
psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. |
2023-08-22 |
2023-09-07 |
human |
| Robert F Dougherty, Patrick Clarke, Merve Atli, Joanna Kuc, Danielle Schlosser, Boadie W Dunlop, David J Hellerstein, Scott T Aaronson, Sidney Zisook, Allan H Young, Robin Carhart-Harris, Guy M Goodwin, Gregory A Rysli. Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. Psychopharmacology. 2023-08-22. PMID:37606733. |
a recent randomized double-blind phase-iib study demonstrated the safety and efficacy of comp360, compass pathways' proprietary synthetic formulation of psilocybin, in participants with treatment-resistant depression. |
2023-08-22 |
2023-09-07 |
human |
| Raul Escamilla, María Eva González-Trujano, Jesús M González Mariscal, Jesús Martín Torres-Valencia, Héctor Guzmán-González, José Luis Vega, Anja Loizaga-Velde. A Proposal to Study the Safety and Efficacy of Journal of psychoactive drugs. 2023-08-18. PMID:37594163. |
psilocybin is today a novel and breakthrough therapy for major depression. |
2023-08-18 |
2023-09-07 |
Not clear |
| Marie Crowe, Jenni Manuel, Dave Carlyle, Cameron Lace. Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy? International journal of mental health nursing. 2023-08-17. PMID:37589380. |
the paper will examine whether three one-to-one psychotherapies identified as effective in the treatment of treatment-resistant depression are compatible with the psilocybin experience. |
2023-08-17 |
2023-09-07 |
Not clear |
| Ayana Jorda. Emerging Perspectives in Addiction Psychiatry. The Journal of clinical psychiatry. vol 84. issue 4. 2023-08-09. PMID:37555675. |
already, some evidence supports the use of psilocybin in alleviating symptoms of depression and anxiety; psychedelic compounds also have potential as alcohol use disorder treatments and may help reduce symptoms tied to opioid withdrawal. |
2023-08-09 |
2023-08-16 |
Not clear |
| b' Natacha Perez, Florent Langlest, Luc Mallet, Marco De Pieri, Othman Sentissi, Gabriel Thorens, Federico Seragnoli, Daniele Zullino, Matthias Kirschner, Stefan Kaiser, Marco Solmi, Michel Sab\\xc3\\xa. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 76. 2023-08-09. PMID:37557019.' |
psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. |
2023-08-09 |
2023-08-16 |
human |
| b' Natacha Perez, Florent Langlest, Luc Mallet, Marco De Pieri, Othman Sentissi, Gabriel Thorens, Federico Seragnoli, Daniele Zullino, Matthias Kirschner, Stefan Kaiser, Marco Solmi, Michel Sab\\xc3\\xa. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 76. 2023-08-09. PMID:37557019.' |
we conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. |
2023-08-09 |
2023-08-16 |
human |
| b' Natacha Perez, Florent Langlest, Luc Mallet, Marco De Pieri, Othman Sentissi, Gabriel Thorens, Federico Seragnoli, Daniele Zullino, Matthias Kirschner, Stefan Kaiser, Marco Solmi, Michel Sab\\xc3\\xa. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 76. 2023-08-09. PMID:37557019.' |
following our protocol (crd 42022220190) multiple electronic databases were searched from their inception until february 2023, to identify double-blind randomized placebo-controlled (rcts) fixed-dose trials evaluating the use of psilocybin for adult patients with primary or secondary depression. |
2023-08-09 |
2023-08-16 |
human |
| Otto Simonsson, Per Carlbring, Robin Carhart-Harris, Alan K Davis, David J Nutt, Roland R Griffiths, David Erritzoe, Simon B Goldber. Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. Psychiatry research. vol 327. 2023-07-31. PMID:37523886. |
we conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (n = 102) with the aim of assessing the risk of symptom worsening. |
2023-07-31 |
2023-08-14 |
human |
| Muhammad Ishrat Husain, Daniel M Blumberger, David J Castle, Nicole Ledwos, Elise Fellows, Brett D M Jones, Abigail Ortiz, Stefan Kloiber, Wei Wang, Joshua D Rosenblat, Benoit H Mulsan. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych open. vol 9. issue 4. 2023-07-25. PMID:37489299. |
psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. |
2023-07-25 |
2023-08-14 |
Not clear |
| Muhammad Ishrat Husain, Daniel M Blumberger, David J Castle, Nicole Ledwos, Elise Fellows, Brett D M Jones, Abigail Ortiz, Stefan Kloiber, Wei Wang, Joshua D Rosenblat, Benoit H Mulsan. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych open. vol 9. issue 4. 2023-07-25. PMID:37489299. |
randomised controlled trials (rcts) of psilocybin have reported large antidepressant effects in adults with major depressive disorder and treatment-resistant depression (trd). |
2023-07-25 |
2023-08-14 |
Not clear |
| Brandon Weiss, Induni Ginige, Lu Shannon, Bruna Giribaldi, Ashleigh Murphy-Beiner, Roberta Murphy, Michelle Baker-Jones, Jonny Martell, David J Nutt, Robin L Carhart-Harris, David Erritzo. Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM. Psychological medicine. 2023-07-19. PMID:37466289. |
personality change in a trial of psilocybin therapy vs escitalopram treatment for depression - corrigendum. |
2023-07-19 |
2023-08-14 |
Not clear |
| Guy M Goodwin, Megan Croal, David Feifel, John R Kelly, Lindsey Marwood, Sunil Mistry, Veronica O'Keane, Stephanie Knatz Peck, Hollie Simmons, Claudia Sisa, Susan C Stansfield, Joyce Tsai, Sam Williams, Ekaterina Malievskai. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-07-14. PMID:37443386. |
psilocybin for treatment resistant depression in patients taking a concomitant ssri medication. |
2023-07-14 |
2023-08-14 |
human |
| Guy M Goodwin, Megan Croal, David Feifel, John R Kelly, Lindsey Marwood, Sunil Mistry, Veronica O'Keane, Stephanie Knatz Peck, Hollie Simmons, Claudia Sisa, Susan C Stansfield, Joyce Tsai, Sam Williams, Ekaterina Malievskai. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-07-14. PMID:37443386. |
psilocybin is being investigated as a treatment in adults with treatment-resistant depression (trd). |
2023-07-14 |
2023-08-14 |
human |
| Bianca Nograd. Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics. BMJ (Clinical research ed.). vol 382. 2023-07-11. PMID:37433614. |
australia's approval of mdma and psilocybin for ptsd and depression is premature, say critics. |
2023-07-11 |
2023-08-14 |
Not clear |